Priyadarshini Yonzon, Ansumali Joshi, Sudarshan Tandukar, Riza Thapa, Pushpa Dahal.
Background: Hyperprolactinemia is a common endocrine disorder. Yet, data on clinical profile of Nepalese patients with hyperprolactinemia is missing. The aim of this study was to assess the clinical profile of Nepalese patients with hyperprolactinemia.
Methodology: This was a retrospective study conducted at Kathmandu Diabetes and Thyroid Center Pvt Ltd, Kathmandu, Nepal. Data was collected from the patient record files of the subjects diagnosed with hyperprolactinemia within the last one and a half year (March 2013 to October 2014). The data was calculated as mean and percentage frequency.
Results: A total of 30 patients diagnosed with hyperprolactinemia were included in the study. Mean age of the patients was 27.3 ± 7.3 years. Menstrual irregularity was the most common presenting problem (48%), followed by galactorrhea (34%). Pituitary adenoma was demonstrated in 37% patients, idiopathic hyperprolactinemia in 33%. Cabergoline was used in 92% patients for treatment of hyperprolactinemia.
Conclusion: Hyperprolactinemia is an important clinical entity with menstrual irregularity and/or galactorrhea as the most common presenting problem. Pituitary adenoma is the major cause of hyperprolactinemia in Nepalese patients. Cabergoline is the drug of choice for treatment of hyperprolactinemia.View pdf